146 related articles for article (PubMed ID: 29227878)
1. Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia.
Kikvidze T; Luhmann N; Avril E; Butsashvili M; Labartkava K; Etienne A; Le Pluart D; Inaridze I; Gamezardashvili A; Kharshiladze D; Bouscaillou J
Int J Drug Policy; 2018 Feb; 52():16-19. PubMed ID: 29227878
[No Abstract] [Full Text] [Related]
2. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment.
Bouscaillou J; Champagnat J; Luhmann N; Avril E; Inaridze I; Miollany V; Labartkava K; Kirtadze I; Butsashvili M; Kamkamidze G; Pataut D
Int J Drug Policy; 2014 Sep; 25(5):871-8. PubMed ID: 24529802
[TBL] [Abstract][Full Text] [Related]
4. People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving.
Dore GJ; Trooskin S
N Engl J Med; 2020 Aug; 383(7):608-611. PubMed ID: 32786185
[No Abstract] [Full Text] [Related]
5. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
[TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
Lucidarme D
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B112-20. PubMed ID: 12180278
[No Abstract] [Full Text] [Related]
7. Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
Schütz A; Moser S; Schwanke C; Schubert R; Luhn J; Gutic E; Lang T; Schleicher M; Haltmayer H; Gschwantler M
J Viral Hepat; 2018 Jul; 25(7):870-873. PubMed ID: 29316001
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of hepatitis C].
Färkkilä M
Duodecim; 1997; 113(11):1061-8. PubMed ID: 11466860
[No Abstract] [Full Text] [Related]
10. [Treatment of hepatitis C in intravenous drug users].
Filoche B
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B252-6. PubMed ID: 12180298
[No Abstract] [Full Text] [Related]
11. Hepatitis C Virus Treatment and Persons Who Inject Drugs.
McCance-Katz EF; Valdiserri RO
Ann Intern Med; 2016 Feb; 164(3):203-4. PubMed ID: 26829915
[No Abstract] [Full Text] [Related]
12. Hepatitis C Virus Treatment and Persons Who Inject Drugs.
Grebely J; Dore GJ; Greenwald R; Swan T; Barua S; Taylor LE
Ann Intern Med; 2016 Feb; 164(3):203. PubMed ID: 26829914
[No Abstract] [Full Text] [Related]
13. Barriers to antiviral treatment in hepatitis C infected intravenous drug users.
Gazdag G; Horvath G; Szabo O; Ungvari GS
Neuropsychopharmacol Hung; 2010 Dec; 12(4):459-62. PubMed ID: 21220790
[TBL] [Abstract][Full Text] [Related]
14. Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
Arain A; Bourgeois S; de Galocsy C; Henrion J; Deltenre P; d'Heygere F; George C; Bastens B; Van Overbeke L; Verrando R; Bruckers L; Mathei C; Buntinx F; Van Vlierberghe H; Francque S; Laleman W; Moreno C; Janssens F; Nevens F; Robaeys G
J Med Virol; 2016 Jan; 88(1):94-9. PubMed ID: 26121975
[TBL] [Abstract][Full Text] [Related]
15. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
[TBL] [Abstract][Full Text] [Related]
16. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs.
Barocas JA
Clin Infect Dis; 2021 Apr; 72(8):1401-1403. PubMed ID: 32166311
[No Abstract] [Full Text] [Related]
17. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
Kåberg M; Hammarberg A; Lidman C; Weiland O
Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
[TBL] [Abstract][Full Text] [Related]
18. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.
Norton BL; Litwin AH
Clin Infect Dis; 2020 May; 70(11):2366-2368. PubMed ID: 31513706
[No Abstract] [Full Text] [Related]
19. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
[TBL] [Abstract][Full Text] [Related]
20. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
Valerio H; McAuley A; Innes H; Palmateer N; Goldberg DJ; Munro A; Taylor A; Hutchinson SJ
Int J Drug Policy; 2018 Feb; 52():115-122. PubMed ID: 29414462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
